Hepatic candidiasis: an increasing problem in immunocompromised patients.
Hepatic candidiasis has been increasingly recognized as a variant of disseminated candidiasis in immunocompromised patients. Five leukemic patients with antemortem diagnosis of hepatic candidiasis are described, and 32 additional cases reported in the literature are reviewed. Cultures of the liver and/or spleen and blood cultures usually give negative results; histopathologic demonstration of Candida organisms in tissue specimens is necessary for a definitive diagnosis. Response to conventional therapy with amphotericin B is poor, and 34.4 percent of the patients died with evidence of active fungal disease. Liposome-encapsulated amphotericin B, which has been successfully used in a limited number of patients with invasive fungal disease, may be an effective and relatively nontoxic drug.
D000328:Adult; D000666:Amphotericin B / Q000627:therapeutic use; D001706:Biopsy; D002175:Candida / Q000302:isolation & purification; D002177:Candidiasis / Q000175:diagnosis* / Q000188:drug therapy / Q000209:etiology / Q000473:pathology; D004359:Drug Therapy, Combination; D005260:Female; D005437:Flucytosine / Q000627:therapeutic use; D006801:Humans; D007153:Immunologic Deficiency Syndromes / Q000150:complications*; D007654:Ketoconazole / Q000627:therapeutic use; D007945:Leukemia, Lymphoid / Q000150:complications; D007951:Leukemia, Myeloid / Q000150:complications; D015470:Leukemia, Myeloid, Acute / Q000150:complications; D008099:Liver / Q000382:microbiology / Q000473:pathology; D008107:Liver Diseases / Q000175:diagnosis* / Q000188:drug therapy / Q000209:etiology / Q000473:pathology; D008297:Male
D000666:Amphotericin B; D005437:Flucytosine; D007654:Ketoconazole